eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| tardive dyskinesia | ||||
| Disease ID | 492 |
|---|---|
| Disease | tardive dyskinesia |
| Definition | iatrogenic extrapyramidal disorder produced by long-term administration of antipsychotic drugs; characterized by oral/lingual/buccal dyskinesias and choreoathetoid movements of the extremities. |
| Synonym | dyskinesia tardive dyskinesia, tardive dyskinesias tardive dyskinesias, tardive dystonia, tardive dystonias, tardive tardive dyskinesia (disorder) tardive dyskinesia -retired- tardive dyskinesia [disease/finding] tardive dyskinesias tardive dystonia tardive dystonias |
| OMIM | |
| UMLS | C0686347 |
| MeSH | |
| SNOMED-CT | |
| Comorbidity | UMLS | Disease | Sentences' Count(Total Sentences:11) C0036341 | schizophrenia | 15 C0221765 | chronic schizophrenia | 2 C0041696 | major depressive disorder | 1 C0039494 | temporomandibular disorder | 1 C0033975 | psychosis | 1 C0013421 | dystonia | 1 C0013384 | dyskinesia | 1 C0036337 | schizoaffective disorder | 1 C0005586 | bipolar disorder | 1 C0040517 | tourette's syndrome | 1 C0030567 | parkinson's disease | 1 |
| Curated Gene | (Waiting for update.) |
| Inferring Gene | Entrez_id | Symbol | Resource(Total Genes:27) 1312 | COMT | CIPHER 1586 | CYP17A1 | CIPHER 1544 | CYP1A2 | CIPHER 1565 | CYP2D6 | CIPHER 1576 | CYP3A4 | CIPHER 1577 | CYP3A5 | CIPHER 1812 | DRD1 | CIPHER 1813 | DRD2 | CIPHER 1814 | DRD3 | CIPHER 1815 | DRD4 | CIPHER 2876 | GPX1 | CIPHER 2944 | GSTM1 | CIPHER 2952 | GSTT1 | CIPHER 3356 | HTR2A | CIPHER 3358 | HTR2C | CIPHER 3362 | HTR6 | CIPHER 4128 | MAOA | CIPHER 4129 | MAOB | CIPHER 4842 | NOS1 | CIPHER 4846 | NOS3 | CIPHER 3164 | NR4A1 | CIPHER 5053 | PAH | CIPHER 283871 | PGP | CIPHER 6531 | SLC6A3 | CIPHER 6532 | SLC6A4 | CIPHER 6648 | SOD2 | CIPHER 7166 | TPH1 | CIPHER |
| Text Mined Gene | (Waiting for update.) |
| Locus | (Waiting for update.) |
| Disease ID | 492 |
|---|---|
| Disease | tardive dyskinesia |
| Integrated Phenotype | HPO | Name(Total Integrated Phenotypes:2) |
| Text Mined Phenotype | HPO | Name | Sentences' Count(Total Phenotypes:12) HP:0100753 | Schizophrenia | 16 HP:0002015 | Swallowing difficulty | 1 HP:0002071 | Extrapyramidal dysfunction | 1 HP:0100543 | Cognitive deficits | 1 HP:0001249 | Mental retardation | 1 HP:0100660 | Dyskinesis | 1 HP:0001332 | Dystonia | 1 HP:0007302 | Bipolar disorder | 1 HP:0000709 | Psychosis | 1 HP:0001300 | Parkinsonism | 1 HP:0001250 | Seizures | 1 HP:0000708 | Behavioral problems | 1 |
| Disease ID | 492 |
|---|---|
| Disease | tardive dyskinesia |
| Manually Symptom | UMLS | Name(Total Manually Symptoms:15) C2364114 | tremor C1963184 | nystagmus C1963154 | renal failure C0558189 | abnormal movement C0427086 | involuntary movements C0422833 | ent symptoms C0393593 | dystonia C0392702 | abnormal involuntary movements C0242422 | parkinsonism C0236830 | neuroleptic-induced parkinsonism C0234507 | anosognosia C0233401 | psychiatric symptoms C0037090 | respiratory symptoms C0026650 | movement disorders C0013384 | abnormal movements |
| Text Mined Symptom | UMLS | Name | Sentences' Count(Total Symptoms:1) |
Manually Genotype(Total Text Mining Genotypes:0) |
|---|
| (Waiting for update.) |
Text Mining Genotype(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
All Snps(Total Genotypes:51) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| snpId | pubmedId | geneId | geneSymbol | diseaseId | sourceId | sentence | score | Year | geneSymbol_dbSNP | CHROMOSOME | POS | REF | ALT |
| rs1045280 | 19049562 | 409 | ARRB2 | umls:C0686347 | BeFree | The coding-synonymous polymorphism rs1045280 (Ser280Ser) in beta-arrestin 2 (ARRB2) gene is associated with tardive dyskinesia in Chinese patients with schizophrenia. | 0.000271442 | 2008 | ARRB2 | 17 | 4719343 | C | T |
| rs1800497 | 18781856 | 6648 | SOD2 | umls:C0686347 | BeFree | Search for these determinants has led to a few consensus associations of CYP2D6 *10, CYP1A2*1F, DRD2 Taq1A (rs1800497), DRD3 Ser9Gly (rs6280) and MnSOD Ala9Val (rs4880) variants with TD. | 0.009544073 | 2008 | ANKK1 | 11 | 113400106 | G | A |
| rs1800497 | 18781856 | 1565 | CYP2D6 | umls:C0686347 | BeFree | Search for these determinants has led to a few consensus associations of CYP2D6 *10, CYP1A2*1F, DRD2 Taq1A (rs1800497), DRD3 Ser9Gly (rs6280) and MnSOD Ala9Val (rs4880) variants with TD. | 0.012529933 | 2008 | ANKK1 | 11 | 113400106 | G | A |
| rs1800497 | 18781856 | 1813 | DRD2 | umls:C0686347 | BeFree | Search for these determinants has led to a few consensus associations of CYP2D6 *10, CYP1A2*1F, DRD2 Taq1A (rs1800497), DRD3 Ser9Gly (rs6280) and MnSOD Ala9Val (rs4880) variants with TD. | 0.01617823 | 2008 | ANKK1 | 11 | 113400106 | G | A |
| rs1800497 | 18781856 | 1544 | CYP1A2 | umls:C0686347 | BeFree | Search for these determinants has led to a few consensus associations of CYP2D6 *10, CYP1A2*1F, DRD2 Taq1A (rs1800497), DRD3 Ser9Gly (rs6280) and MnSOD Ala9Val (rs4880) variants with TD. | 0.005895776 | 2008 | ANKK1 | 11 | 113400106 | G | A |
| rs1800497 | 18781856 | 1814 | DRD3 | umls:C0686347 | BeFree | Search for these determinants has led to a few consensus associations of CYP2D6 *10, CYP1A2*1F, DRD2 Taq1A (rs1800497), DRD3 Ser9Gly (rs6280) and MnSOD Ala9Val (rs4880) variants with TD. | 0.03654764 | 2008 | ANKK1 | 11 | 113400106 | G | A |
| rs1800566 | 18977034 | 1728 | NQO1 | umls:C0686347 | BeFree | Additive effect between quinine oxidoreductase gene (NQO1: Pro187Ser) and manganese superoxide dismutase gene (MnSOD: Ala-9Val) polymorphisms on tardive dyskinesia in patients with schizophrenia. | 0.001357209 | 2008 | NQO1 | 16 | 69711242 | G | A |
| rs1800566 | 18977034 | 6648 | SOD2 | umls:C0686347 | BeFree | Additive effect between quinine oxidoreductase gene (NQO1: Pro187Ser) and manganese superoxide dismutase gene (MnSOD: Ala-9Val) polymorphisms on tardive dyskinesia in patients with schizophrenia. | 0.009544073 | 2008 | NQO1 | 16 | 69711242 | G | A |
| rs1800566 | 18977034 | 8630 | HSD17B6 | umls:C0686347 | BeFree | Additive effect between quinine oxidoreductase gene (NQO1: Pro187Ser) and manganese superoxide dismutase gene (MnSOD: Ala-9Val) polymorphisms on tardive dyskinesia in patients with schizophrenia. | 0.000271442 | 2008 | NQO1 | 16 | 69711242 | G | A |
| rs1800566 | 18977034 | 7296 | TXNRD1 | umls:C0686347 | BeFree | Additive effect between quinine oxidoreductase gene (NQO1: Pro187Ser) and manganese superoxide dismutase gene (MnSOD: Ala-9Val) polymorphisms on tardive dyskinesia in patients with schizophrenia. | 0.000271442 | 2008 | NQO1 | 16 | 69711242 | G | A |
| rs1800566 | 19778569 | 1666 | DECR1 | umls:C0686347 | BeFree | (2004) originally reported a significant association between TD and the NADPH quinine oxidoreductase 1 (NQO1) gene Pro187Ser (C609T, rs1800566) polymorphism in Korean schizophrenia patients; however, subsequent studies have not consistently replicated these findings. | 0.000271442 | 2010 | NQO1 | 16 | 69711242 | G | A |
| rs1800566 | 19778569 | 1728 | NQO1 | umls:C0686347 | BeFree | (2004) originally reported a significant association between TD and the NADPH quinine oxidoreductase 1 (NQO1) gene Pro187Ser (C609T, rs1800566) polymorphism in Korean schizophrenia patients; however, subsequent studies have not consistently replicated these findings. | 0.001357209 | 2010 | NQO1 | 16 | 69711242 | G | A |
| rs1800955 | 17556853 | 1815 | DRD4 | umls:C0686347 | BeFree | No association between dopamine D4 receptor gene -521 C/T polymorphism and tardive dyskinesia in schizophrenia. | 0.008458305 | 2007 | DRD4 | 11 | 636784 | T | C |
| rs1801028 | 16160620 | 1813 | DRD2 | umls:C0686347 | BeFree | This study tested the association between tardive dyskinesia (TD) and polymorphic variations in (a) 2 cytochrome P450 (CYP) genes (CYP2D6 or CYP3A5), (b) 2 DRD2 variants (Ser311Cys and -141C Ins/del) and the Ser9Gly DRD3 variants, (c) 2 glutathione S-transferases (GSTT1 and GSTM1), and (d) variations in the PgP gene, MDR1. | 0.01617823 | 2005 | DRD2 | 11 | 113412762 | G | C |
| rs1801028 | 16160620 | 9360 | PPIG | umls:C0686347 | BeFree | This study tested the association between tardive dyskinesia (TD) and polymorphic variations in (a) 2 cytochrome P450 (CYP) genes (CYP2D6 or CYP3A5), (b) 2 DRD2 variants (Ser311Cys and -141C Ins/del) and the Ser9Gly DRD3 variants, (c) 2 glutathione S-transferases (GSTT1 and GSTM1), and (d) variations in the PgP gene, MDR1. | 0.000814326 | 2005 | DRD2 | 11 | 113412762 | G | C |
| rs1805054 | 12057822 | 3362 | HTR6 | umls:C0686347 | BeFree | Genetic association analysis of 5-HT(6) receptor gene polymorphism (267C/T) with tardive dyskinesia. | 0.000271442 | 2002 | HTR6 | 1 | 19666020 | C | T |
| rs377591409 | 15118351 | 1565 | CYP2D6 | umls:C0686347 | BeFree | We concluded that the CYP2D6*10 C188T polymorphism may be associated with the susceptibility to the occurrence of TD induced by typical antipsychotics, especially in male patients, and may also be correlated with AIMS scores in TD patients. | 0.012529933 | 2004 | CYP2D6;LOC102723722 | 22 | 42129173 | G | A,T |
| rs386602118 | 22695185 | 627 | BDNF | umls:C0686347 | BeFree | Brain-derived neurotrophic factor levels and its Val66Met gene polymorphism predict tardive dyskinesia treatment response to Ginkgo biloba. | 0.003995683 | 2012 | NA | NA | NA | NA | NA |
| rs386602118 | 18602732 | 627 | BDNF | umls:C0686347 | BeFree | No association between the brain-derived neurotrophic factor gene Val66Met polymorphism and tardive dyskinesia in schizophrenic patients. | 0.003995683 | 2008 | NA | NA | NA | NA | NA |
| rs386602118 | 15626824 | 627 | BDNF | umls:C0686347 | BeFree | Association analysis of the dopamine D3 receptor gene ser9gly and brain-derived neurotrophic factor gene val66met polymorphisms with antipsychotic-induced persistent tardive dyskinesia and clinical expression in Chinese schizophrenic patients. | 0.003995683 | 2004 | NA | NA | NA | NA | NA |
| rs386602280 | 15861931 | 3356 | HTR2A | umls:C0686347 | BeFree | The 9Gly-variant of the dopamine D3 receptor, the 102C-variant, but not the His452Tyr polymorphism of the 5-HT2A-receptor and the 23Ser-variant (for females only) of the 5-HT2C receptor seem to increase the susceptibility to tardive dyskinesia. | 0.009815515 | 2005 | NA | NA | NA | NA | NA |
| rs386602280 | 15861931 | 3358 | HTR2C | umls:C0686347 | BeFree | The 9Gly-variant of the dopamine D3 receptor, the 102C-variant, but not the His452Tyr polymorphism of the 5-HT2A-receptor and the 23Ser-variant (for females only) of the 5-HT2C receptor seem to increase the susceptibility to tardive dyskinesia. | 0.005819831 | 2005 | NA | NA | NA | NA | NA |
| rs386602280 | 15861931 | 1814 | DRD3 | umls:C0686347 | BeFree | The 9Gly-variant of the dopamine D3 receptor, the 102C-variant, but not the His452Tyr polymorphism of the 5-HT2A-receptor and the 23Ser-variant (for females only) of the 5-HT2C receptor seem to increase the susceptibility to tardive dyskinesia. | 0.03654764 | 2005 | NA | NA | NA | NA | NA |
| rs4680 | 18180754 | 6648 | SOD2 | umls:C0686347 | BeFree | Evidence from pooled data for genetic association with tardive dyskinesia (TD) showed (1) in COMT(val158met), using Val-Val homozygotes as reference category, a protective effect for Val-Met heterozygotes (OR=0.63, 95% CI: 0.46-0.86, P=0.004) and Met carriers (OR=0.66, 95% CI: 0.49-0.88, P=0.005); (2) in Taq1A in DRD2, using the A1 variant as reference category, a risk-increasing effect for the A2 variant (OR=1.30, 95% CI: 1.03-1.65, P=0.026), and A2-A2 homozygotes using A1-A1 as reference category (OR=1.80, 95% CI: 1.03-3.15, P=0.037); (3) in MnSOD Ala-9Val, using Ala-Ala homozygotes as reference category, a protective effect for Ala-Val (OR=0.37, 95% CI: 0.17-0.79, P=0.009) and for Val carriers (OR=0.49, 95% CI: 0.24-1.00, P=0.047). | 0.009544073 | 2008 | COMT;MIR4761 | 22 | 19963748 | G | A |
| rs4680 | 15583953 | 1312 | COMT | umls:C0686347 | BeFree | Negative association between catechol-O-methyltransferase (COMT) gene Val158Met polymorphism and persistent tardive dyskinesia in schizophrenia. | 0.001628651 | 2005 | COMT;MIR4761 | 22 | 19963748 | G | A |
| rs4680 | 18180754 | 1813 | DRD2 | umls:C0686347 | BeFree | Evidence from pooled data for genetic association with tardive dyskinesia (TD) showed (1) in COMT(val158met), using Val-Val homozygotes as reference category, a protective effect for Val-Met heterozygotes (OR=0.63, 95% CI: 0.46-0.86, P=0.004) and Met carriers (OR=0.66, 95% CI: 0.49-0.88, P=0.005); (2) in Taq1A in DRD2, using the A1 variant as reference category, a risk-increasing effect for the A2 variant (OR=1.30, 95% CI: 1.03-1.65, P=0.026), and A2-A2 homozygotes using A1-A1 as reference category (OR=1.80, 95% CI: 1.03-3.15, P=0.037); (3) in MnSOD Ala-9Val, using Ala-Ala homozygotes as reference category, a protective effect for Ala-Val (OR=0.37, 95% CI: 0.17-0.79, P=0.009) and for Val carriers (OR=0.49, 95% CI: 0.24-1.00, P=0.047). | 0.01617823 | 2008 | COMT;MIR4761 | 22 | 19963748 | G | A |
| rs4880 | 18781856 | 1814 | DRD3 | umls:C0686347 | BeFree | Search for these determinants has led to a few consensus associations of CYP2D6 *10, CYP1A2*1F, DRD2 Taq1A (rs1800497), DRD3 Ser9Gly (rs6280) and MnSOD Ala9Val (rs4880) variants with TD. | 0.03654764 | 2008 | SOD2 | 6 | 159692840 | A | G |
| rs4880 | 18781856 | 6648 | SOD2 | umls:C0686347 | BeFree | Search for these determinants has led to a few consensus associations of CYP2D6 *10, CYP1A2*1F, DRD2 Taq1A (rs1800497), DRD3 Ser9Gly (rs6280) and MnSOD Ala9Val (rs4880) variants with TD. | 0.009544073 | 2008 | SOD2 | 6 | 159692840 | A | G |
| rs4880 | 18781856 | 1544 | CYP1A2 | umls:C0686347 | BeFree | Search for these determinants has led to a few consensus associations of CYP2D6 *10, CYP1A2*1F, DRD2 Taq1A (rs1800497), DRD3 Ser9Gly (rs6280) and MnSOD Ala9Val (rs4880) variants with TD. | 0.005895776 | 2008 | SOD2 | 6 | 159692840 | A | G |
| rs4880 | 18781856 | 1813 | DRD2 | umls:C0686347 | BeFree | Search for these determinants has led to a few consensus associations of CYP2D6 *10, CYP1A2*1F, DRD2 Taq1A (rs1800497), DRD3 Ser9Gly (rs6280) and MnSOD Ala9Val (rs4880) variants with TD. | 0.01617823 | 2008 | SOD2 | 6 | 159692840 | A | G |
| rs4880 | 18781856 | 1565 | CYP2D6 | umls:C0686347 | BeFree | Search for these determinants has led to a few consensus associations of CYP2D6 *10, CYP1A2*1F, DRD2 Taq1A (rs1800497), DRD3 Ser9Gly (rs6280) and MnSOD Ala9Val (rs4880) variants with TD. | 0.012529933 | 2008 | SOD2 | 6 | 159692840 | A | G |
| rs6280 | 16513329 | 1814 | DRD3 | umls:C0686347 | BeFree | Antipsychotic-induced tardive dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: a meta analysis. | 0.03654764 | 2006 | DRD3 | 3 | 114171968 | C | T |
| rs6280 | 18781856 | 1813 | DRD2 | umls:C0686347 | BeFree | Search for these determinants has led to a few consensus associations of CYP2D6 *10, CYP1A2*1F, DRD2 Taq1A (rs1800497), DRD3 Ser9Gly (rs6280) and MnSOD Ala9Val (rs4880) variants with TD. | 0.01617823 | 2008 | DRD3 | 3 | 114171968 | C | T |
| rs6280 | 12109967 | 1814 | DRD3 | umls:C0686347 | BeFree | Association of the Ser9Gly polymorphism in the dopamine D3 receptor gene with tardive dyskinesia in Korean schizophrenics. | 0.03654764 | 2002 | DRD3 | 3 | 114171968 | C | T |
| rs6280 | 19238168 | 1814 | DRD3 | umls:C0686347 | BeFree | Thus, a number of studies have focused on the association of dopamine system gene polymorphisms and TD, with the most consistent findings being an association between TD and the Ser9Gly polymorphism of the DRD3 gene and the TaqIA site 3' of the DRD2 gene. | 0.03654764 | 2009 | DRD3 | 3 | 114171968 | C | T |
| rs6280 | 18562401 | 1814 | DRD3 | umls:C0686347 | BeFree | This study investigated the possible relationship between TD and the polymorphisms Ser9Gly (DRD3), 102T>C (HTR2A), -1438G>A(HTR2A) and Cys23Ser (HTR2C) in African-Caribbean inpatients. | 0.03654764 | 2009 | DRD3 | 3 | 114171968 | C | T |
| rs6280 | 18781856 | 1544 | CYP1A2 | umls:C0686347 | BeFree | Search for these determinants has led to a few consensus associations of CYP2D6 *10, CYP1A2*1F, DRD2 Taq1A (rs1800497), DRD3 Ser9Gly (rs6280) and MnSOD Ala9Val (rs4880) variants with TD. | 0.005895776 | 2008 | DRD3 | 3 | 114171968 | C | T |
| rs6280 | 11490179 | 1814 | DRD3 | umls:C0686347 | BeFree | Association between the Ser9Gly polymorphism of the dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients. | 0.03654764 | 2001 | DRD3 | 3 | 114171968 | C | T |
| rs6280 | 18781856 | 1814 | DRD3 | umls:C0686347 | BeFree | Search for these determinants has led to a few consensus associations of CYP2D6 *10, CYP1A2*1F, DRD2 Taq1A (rs1800497), DRD3 Ser9Gly (rs6280) and MnSOD Ala9Val (rs4880) variants with TD. | 0.03654764 | 2008 | DRD3 | 3 | 114171968 | C | T |
| rs6280 | 18781856 | 6648 | SOD2 | umls:C0686347 | BeFree | Search for these determinants has led to a few consensus associations of CYP2D6 *10, CYP1A2*1F, DRD2 Taq1A (rs1800497), DRD3 Ser9Gly (rs6280) and MnSOD Ala9Val (rs4880) variants with TD. | 0.009544073 | 2008 | DRD3 | 3 | 114171968 | C | T |
| rs6280 | 18781856 | 1565 | CYP2D6 | umls:C0686347 | BeFree | Search for these determinants has led to a few consensus associations of CYP2D6 *10, CYP1A2*1F, DRD2 Taq1A (rs1800497), DRD3 Ser9Gly (rs6280) and MnSOD Ala9Val (rs4880) variants with TD. | 0.012529933 | 2008 | DRD3 | 3 | 114171968 | C | T |
| rs6280 | 12062911 | 1814 | DRD3 | umls:C0686347 | BeFree | Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. | 0.03654764 | 2002 | DRD3 | 3 | 114171968 | C | T |
| rs6280 | 19358223 | 1814 | DRD3 | umls:C0686347 | BeFree | The DRD3 rs6280 polymorphism and prevalence of tardive dyskinesia: a meta-analysis. | 0.03654764 | 2010 | DRD3 | 3 | 114171968 | C | T |
| rs6280 | 16160620 | 1814 | DRD3 | umls:C0686347 | BeFree | Two gene variants appeared to be significant after adding them to the clinical regression models: (1) Ser9Gly DRD3 polymorphism was associated with severe TD (odds ratio for patients with 1 mutant allele when compared with individuals with 2 wild types was 2.5, 95% confidence interval 1.1-5.6, whereas the odds ratio for patients with 2 mutant alleles when compared with individuals with 1 mutant was 2.8, 95% confidence interval 1.0-7.4), and (2) GSTM1 absence was associated with TD (odds ratio 1.7, 95% confidence interval 1.2-2.4) particularly in white women. | 0.03654764 | 2005 | DRD3 | 3 | 114171968 | C | T |
| rs6280 | 16160620 | 9360 | PPIG | umls:C0686347 | BeFree | This study tested the association between tardive dyskinesia (TD) and polymorphic variations in (a) 2 cytochrome P450 (CYP) genes (CYP2D6 or CYP3A5), (b) 2 DRD2 variants (Ser311Cys and -141C Ins/del) and the Ser9Gly DRD3 variants, (c) 2 glutathione S-transferases (GSTT1 and GSTM1), and (d) variations in the PgP gene, MDR1. | 0.000814326 | 2005 | DRD3 | 3 | 114171968 | C | T |
| rs6280 | 16160620 | 1813 | DRD2 | umls:C0686347 | BeFree | This study tested the association between tardive dyskinesia (TD) and polymorphic variations in (a) 2 cytochrome P450 (CYP) genes (CYP2D6 or CYP3A5), (b) 2 DRD2 variants (Ser311Cys and -141C Ins/del) and the Ser9Gly DRD3 variants, (c) 2 glutathione S-transferases (GSTT1 and GSTM1), and (d) variations in the PgP gene, MDR1. | 0.01617823 | 2005 | DRD3 | 3 | 114171968 | C | T |
| rs6280 | 22172931 | 1814 | DRD3 | umls:C0686347 | BeFree | Genetic association between the dopamine D3 receptor gene polymorphism (Ser9Gly) and tardive dyskinesia in patients with schizophrenia: a reevaluation in East Asian populations. | 0.03654764 | 2012 | DRD3 | 3 | 114171968 | C | T |
| rs72393728 | 23951054 | 80199 | FUZ | umls:C0686347 | BeFree | Rs1800872 and rs72393728 were genotyped in schizophrenic patients with TD (n = 372) and without TD (NTD; n = 412). | 0.000271442 | 2013 | NA | NA | NA | NA | NA |
| rs7669317 | 21907090 | 2736 | GLI2 | umls:C0686347 | BeFree | Moreover, the application of the genome-wide association study (GWAS) to the susceptibility of TD has revealed certain associated genes that previously were never considered to be associated with TD, such as the rs7669317 on 4q24, GLI2 gene, GABA pathway genes, and HSPG2 gene. | 0.000542884 | 2011 | NA | 4 | 105536173 | T | C |
| rs7669317 | 21907090 | 3339 | HSPG2 | umls:C0686347 | BeFree | Moreover, the application of the genome-wide association study (GWAS) to the susceptibility of TD has revealed certain associated genes that previously were never considered to be associated with TD, such as the rs7669317 on 4q24, GLI2 gene, GABA pathway genes, and HSPG2 gene. | 0.000814326 | 2011 | NA | 4 | 105536173 | T | C |
| rs76980269 | 15088155 | 4842 | NOS1 | umls:C0686347 | BeFree | We concluded that the NOS1 3'-UTR C276T polymorphism might not play a major role in the susceptibility of TD development, or on the severity of TD. | 0.000542884 | 2004 | NOS1 | 12 | 117330794 | G | A |
GWASdb Annotation(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Snp Trait(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
Mapped by lexical matching(Total Items:1) | ||||
|---|---|---|---|---|
| HP ID | HP Name | MP ID | MP Name | Annotation |
| HP:0000707 | Abnormality of the nervous system | MP:0013620 | increased internal diameter of femur | increased cross-sectional distance that extends from one lateral edge of the femur long bone marrow cavity, through its center and to the opposite lateral edge of the bone marrow cavity through the mid point of the femur |
Mapped by homologous gene(Total Items:1) | ||||
|---|---|---|---|---|
| HP ID | HP Name | MP ID | MP Name | Annotation |
| HP:0000707 | Abnormality of the nervous system | MP:0020254 | decreased collagen level | decreased level of the main structural protein of the various connective tissues in animals |
| Disease ID | 492 |
|---|---|
| Disease | tardive dyskinesia |
| Case | (Waiting for update.) |